GLP 1s - One Class of Drugs with Many Different Names

Taking Control Of Your Diabetes® - The Podcast!

Content provided by Taking Control Of Your Diabetes®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taking Control Of Your Diabetes® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

4M ago 34:43

MP3•Episode home

In this episode, Dr. Jeremy Pettus and Dr. Steve Edelman go head-to-head in a friendly face-off between two of the most talked-about medications in diabetes and weight management: Ozempic and Mounjaro. Both are part of the powerful GLP-1 class, but which one might be better for you? From A1C reduction and weight loss to heart and kidney protection, ease of use, side effects, and insurance coverage—Drs. E & P walk you through a category-by-category comparison. They bring the clinical data and their own real-world patient experience to help you understand the key differences (and similarities) between these leading therapies. Whether you're managing type 2 diabetes, living with type 1, or exploring options for weight loss, this episode is designed to help you make an informed decision with your healthcare provider.

Key Topics:

How These Medications Work: Learn the difference between GLP-1 and dual agonist therapies
A1C Reduction: See which drug leads to greater blood sugar improvements based on head-to-head clinical trials.
Weight Loss: Discover how much weight patients lose on each medication—and why Mounjaro often shows stronger results.
Heart Health: Understand which medication has FDA approval for cardiovascular protection and what’s still under investigation.
Kidney Protection: Explore the latest studies showing Ozempic’s ability to slow kidney disease progression.
Side Effects: Get practical tips on managing common GI side effects and why titration matters.
Ease of Use: Compare how the pens work, dosing flexibility, and what may be easier for patients day to day.
Sleep Apnea: Find out how Mounjaro earned a new indication for reducing sleep apnea severity—especially through weight loss.
Access for Type 1s: Learn why these meds aren’t yet approved for T1D and how some patients are still getting them.
Emerging Indications: Hear about new uses for these meds, including fatty liver, osteoarthritis, and even alcohol reduction.
How to Choose: Get expert guidance on which medication may be right for you based on your goals and health needs.

★ Support this podcast ★

82 episodes

#Non-Profit #Business #Podcasting Education #TCOYD #Diabetes #Type 1 #Type 2 #Health and Well-Being #Health Care Professional #Medicine #Wellness #Doctor Who #Endocrinologists #Science